This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs |
Toxicity |
Mechanism |
Reference |
|---|
| Captopril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Enalapril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Fluvastatin | Atherosclerosis | Lipid changes (e.g.@ reductions in low-density lipoprotein cholesterol and apolipoprotein B);progression or regression of coronary atherosclerosis [ ADR Type 1 ] | Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction
|
| Fosinopril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function. [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| imidapril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function. [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Lisinopril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Moexipril hydrochloride | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function. [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Perindopril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Quinapril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Ramipril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|
| Sertraline | Hyporeflexia | Not Available | Large-scale prediction and testing of drug activity on side-effect targets
|
| Tramadol | Dry Mouth | Not Available | Large-scale prediction and testing of drug activity on side-effect targets
|
| Trandolapril | Bradycardia | Renoprotective effects@ blood-pressure reduction@ reduction in left ventricular mass@ endothelial function. [ ADR Type 1 ] | Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion/deletion polymorphism Kidney
|